The role of nurses in the management of adverse events in patients receiving first-line Axitinib plus immuno-oncology agents for advanced renal cell carcinoma

Parreira, Sara, Burns, Kathleen, Moldawer, Nancy, Zomordian, Nazy, Bandali, Nesan, Virdee, Kiran, Walsh, Meghara, Kelly, Daniel ORCID: https://orcid.org/0000-0002-1847-0655, Rao, Dharanija, Teresi, Rosemary and Wood, Laura S. 2024. The role of nurses in the management of adverse events in patients receiving first-line Axitinib plus immuno-oncology agents for advanced renal cell carcinoma. Seminars in Oncology Nursing 40 (1) , 151545. 10.1016/j.soncn.2023.151545

PDF - Published Version Available under License Creative Commons Attribution. Download (2MB)

Abstract

The recent approval of first-line tyrosine kinase inhibitor plus immuno-oncology agent combination therapy for the treatment of advanced renal cell carcinoma offers substantially improved response rates and survival compared with the previous standard of care. This expansion of treatment options has also led to a greater range and complexity of potential treatment-related adverse events related to overlapping toxicities. The aim of this article is to discuss the management of common treatment-emergent adverse events (AEs) associated with axitinib plus immuno-oncology therapy, highlight the specific roles of oncology nurses in managing these events, and provide AE management resources to aid oncology nurses in their care of patients with advanced renal cell carcinoma.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Healthcare Sciences
Publisher:	Elsevier
ISSN:	0749-2081
Date of First Compliant Deposit:	29 November 2023
Last Modified:	18 Mar 2024 12:01
URI:	https://orca.cardiff.ac.uk/id/eprint/164438

Actions (repository staff only)

Edit Item